Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO) - Turner, N C; Telli, M L; Rugo, H S (J Clin Oncol, 2017)
(Suppl.)